

Panel: Care After Cardiac Arrest Needs Upgrade

BY MITCHEL L. ZOLER

An expert panel convened by the American Heart Association issued a call to action for the creation of U.S. regional systems of care for patients resuscitated from out-of-hospital cardiac arrest.

"We believe that the time has come for a call to develop and implement standards for regional systems of care for those with restoration of circulation after OOHCA [out-of-hospital cardiac arrest]," wrote the 19-member panel convened by the American Heart Association, the American College of Emergency Physicians, and the National Association of State EMS Officials.

"Successful implementation and maintenance of cardiac resuscitation systems of care would have a significant and important impact on the third-leading cause of death in the United States. The time to implement these systems of care is now," the panel said in its statement (Circulation 2010 Jan. 14 [doi:10.1161/CIR.0b013e3181cdb7db]).

"It will take action by the American Heart Association, which endorsed the statement, as well as by the other organizations that endorsed this, to work together to make sure this happens," Dr. Graham Nichol, chairman of the panel, said in an interview. "There is pent-up demand [among physicians] to help these patients, and it is already happening in some places" in the United States, said Dr. Nichol, professor of medicine at the University of Washington in Seattle.

"The trauma system of care is a good model," Dr. Nichol said. "Prehospital providers, trauma surgeons, and emergency doctors worked together for many years to create a certification process. That's the model we're advocating for."

OOHCA affects an estimated 300,000 Americans annually, and is the third-leading cause of U.S. deaths. The panel cited a fivefold regional variation in the outcome of OOHCA patients treated by emergency medical services among sites in the Resuscitation Outcomes Consortium. This regional variation "demonstrates that it is a treatable condition," said Dr. Nichol, who is also director and chair of the Medic One Foundation of the Harborview Center for Prehospital Emergency Care in Seattle.

Regional systems of care for these patients exist in a few locations, including Seattle, the state of Arizona, and areas of Minnesota, New York, Ohio, Texas, and Virginia. In Seattle, the survival-to-hospital-discharge rate among OOHCA patients is 16% for patients with any type of initial rhythm disturbance, and 40% among patients with ventricular fibrillation. For North America overall, the median survival rate is 8%.

Proven, effective interventions for OOHCA patients include therapeutic hypothermia, early percutaneous coronary intervention, early prognostication of patient outcomes, and use of implantable cardioverter defibrillators. Promising interventions that require spe-

cial expertise to ensure their successful use include glucose control, seizure control, cardiopulmonary support, and hemofiltration, the statement said.

The proposal envisions three levels of care within a regional system: emergency medical services, level 2 cardiac resuscitation centers, and level 1 cardiac resuscitation centers. Level 1 centers would have the capability to perform primary percutaneous coronary inter-

ventions, electrophysiology testing, and placement of implantable cardioverter-defibrillators; assess prognosis; provide all services 24/7; and treat at least 40 patients resuscitated from OOHCA annually. Level 2 centers would not have these features and services, but would be capable of initiating hypothermia and providing CPR and advanced cardiac life support training for staff. In addition, they would be mandated to quickly

transport patients to a level 1 facility.

Both level 1 and 2 centers as well as emergency medical services would receive external certification.

Starting such a regional system of coordinated care for OOHCA patients will take "a large group of individuals from different specialties to come together," Dr. Nichol said. The stakeholders who need to be involved in creating these systems include emergency medical services



Same Name. New Size.

Introducing 3 mL of Humalog® and Humulin® R U-100 in a Smaller Vial*

The New Smaller Vial, Another Insulin Delivery Option

Intended To: Give hospitals more flexibility when evaluating insulin storage and distribution (floor stock vs individual patient supply), in addition to the 10 mL vial and Humalog® KwikPen™.

- **Same Bar-Coding Technique, New Size**
- **Same Color-Differentiating System, New Size**
- **National Drug Code (NDC)**

Humalog - NDC Number - 0002-7510-17

Humulin R U-100 - NDC Number - 0002-8215-17

Indication

Humalog is for use in patients with diabetes mellitus for the control of hyperglycemia. Humalog should be used with longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.

Select Safety Information

Hypoglycemia is the most common adverse effect associated with insulins, including Humalog.

When used as a mealtime insulin, Humalog should be given within 15 minutes before or immediately after a meal.

*3 mL of Humalog and Humulin R U-100 are in a 5 mL vial.

Pens are for single-patient use only and should not be shared among patients.

Please see Important Safety Information on adjacent page and accompanying Brief Summary of full Prescribing Information.

Humalog
insulin lispro injection (rDNA origin)

physicians, emergency physicians, cardiologists, and critical care physicians, as well as nurses and medics.

“Each community likely needs a local champion who can implement and maintain a culture of change to achieve broad and sustained improvement in outcomes. But one person cannot do this alone,” he added. ■

Disclosures: Dr. Nichol reported relationships with Laerdal Inc., Physio-Control Inc., and Channing Bele Inc. Other members of the panel reported a variety of commercial relationships.

MY TAKE

ICUs Could End Up Treating More Cardiac Arrest Survivors

It’s reasonable to expect that regional systems of care, which have improved the outcomes of trauma and stroke patients, also could produce benefits for cardiac arrest patients. The cardiac arrest system could be built on top of the existing trauma and stroke regional systems. Several elements that



the AHA

calls for in level 1 cardiac arrest centers, such as 24/7 availability of percutaneous coronary intervention and electrophysiology services, are already in place at level 1 trauma centers. But most trauma and stroke centers lack the capability to deliver therapeutic hypothermia.

For hospitalists, the potential impact

from improved cardiac arrest care would occur downstream, as more cardiac arrest patients survive their acute episode and require intensive care during their recovery.

DR. ALPESH AMIN, professor and chairman of medicine at the University of California, Irvine, and executive director of its hospitalist program, reported no relevant disclosures.

Indication

Humalog (insulin lispro injection [rDNA origin]) is for use in patients with diabetes mellitus for the control of hyperglycemia. Humalog should be used with longer-acting insulin, except when used in combination with sulfonylureas in patients with type 2 diabetes.

Important Safety Information

Humalog is contraindicated during episodes of hypoglycemia and in patients sensitive to Humalog or one of its excipients.

Humalog differs from regular human insulin by its rapid onset of action as well as a shorter duration of action. Therefore, when used as a mealtime insulin, Humalog should be given within 15 minutes before or immediately after a meal.

Due to the short duration of action of Humalog, patients with type 1 diabetes also require a longer-acting insulin to maintain glucose control (except when using an insulin pump). Glucose monitoring is recommended for all patients with diabetes.

The safety and effectiveness of Humalog in patients less than 3 years of age have not been established. There are no adequate and well-controlled clinical studies of the use of Humalog in pregnant or nursing women.

Starting or changing insulin therapy should be done cautiously and only under medical supervision.

Hypoglycemia

Hypoglycemia is the most common adverse effect associated with insulins, including Humalog. Hypoglycemia can happen suddenly, and symptoms may be different for each person and may change from time to time. Severe hypoglycemia can cause seizures and may be life-threatening.

Other Side Effects

Other potential side effects associated with the use of insulins include: hypokalemia, weight gain, lipodystrophy, and hypersensitivity. Systemic allergy is less common, but may be life-threatening. Because of the difference in action of Humalog, care should be taken in patients in whom hypoglycemia or hypokalemia may be clinically relevant (eg, those who are fasting, have autonomic neuropathy or renal impairment, are using potassium-lowering drugs, or taking drugs sensitive to serum potassium level).

For additional safety profile and other important prescribing considerations, see accompanying Brief Summary of full Prescribing Information.

Please see full user manual that accompanies the pen.

Humalog® is a registered trademark of Eli Lilly and Company and is available by prescription only. Humalog® KwikPen™ is a trademark of Eli Lilly and Company and is available by prescription only. Humulin® is a registered trademark of Eli Lilly and Company.

